Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624450 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
A Phase 3 study of Viral Lung Infection and Acute Respiratory Failure, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,870
- Enrollment target
- 20
- Study locations
NCT05624450: Recruiting Phase 3 study of Viral Lung Infection and Acute Respiratory Failure, sponsored by AstraZeneca.
NCT05624450 is a Phase 3 study of Viral Lung Infection and Acute Respiratory Failure that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 2,870 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (272% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05624450, a Phase 3 study of Viral Lung Infection and Acute Respiratory Failure, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,870 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Primary Outcome
To evaluate the effect of tozorakimab versus placebo as an add on to Standard of Care (SoC) in participants with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tozorakimab
Study Locations (20)
Florida
- Research Site - Bradenton
- Research Site - Bradenton
- Research Site - Gainesville
- Research Site - Jacksonville
- Research Site - Lakeland
- Research Site - Miami
- Research Site - South Pasadena
California
- Research Site - Chula Vista
- Research Site - Fresno
- Research Site - La Mesa
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - Torrance
Arizona
- Research Site - Phoenix
- Research Site - Phoenix
- Research Site - Tucson
Colorado
- Research Site - Colorado Springs
- Research Site - Denver
Alabama
- Research Site - Mobile
District of Columbia
- Research Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,870 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2026-06-19 |
| Phase | Phase 3 |
What NCT05624450 shows while recruiting
NCT05624450 is an interventional study that assigns participants to a tested intervention. Its 2,870 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (272% higher).
The record links to 1 condition, with Viral Lung Infection and Acute Respiratory Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05624450 names 20 study sites across 6 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05624450 about?
NCT05624450 is a clinical study titled "Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen". The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
What is the current status of trial NCT05624450?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,870 participants. The study started on 2022-12-13. Estimated completion is 2026-06-19.
What conditions does trial NCT05624450 study?
This clinical trial studies the following conditions: Viral Lung Infection and Acute Respiratory Failure.
What interventions are being tested in trial NCT05624450?
The interventions under investigation include: Placebo (DRUG), Tozorakimab (DRUG).
Who is sponsoring clinical trial NCT05624450?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05624450 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05624450's enrollment target sits among peer trials
2,870 80th of 2000 higher than 1,921 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT06150781 · 2,842 participants
Aimovig Pregnancy Exposure Registry
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI